Literature DB >> 3386403

Catechol-O-methyltransferase activity in human and rat small intestine.

E Nissinen1, R Tuominen, V Perhoniemi, S Kaakkola.   

Abstract

The activities of soluble (S-COMT) and membrane-bound (MB-COMT) forms of catechol-O-methyltransferase in different regions of human and rat small intestine were determined. S-COMT was the predominant form both in the mucous membrane and in the muscle layers. The activity of S-COMT was more than twice as high in the mucous membrane as in the muscle layer. The activity of MB-COMT was almost equal in the different regions of the gut as well as in the mucous membrane and muscle layers. However, the ratio of the soluble form to the membrane-bound form was close to one in the human muscle layers of the jejunum and ileum.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3386403     DOI: 10.1016/0024-3205(88)90330-x

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  12 in total

1.  Preventive effect of rikkunshito on gastric motor function inhibited by L-dopa in rats.

Authors:  Lixin Wang; Sachiko Mogami; Hiroshi Karasawa; Chihiro Yamada; Seiichi Yakabi; Koji Yakabi; Tomohisa Hattori; Yvette Taché
Journal:  Peptides       Date:  2014-03-11       Impact factor: 3.750

2.  Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.

Authors:  T Müller; C Erdmann; S Muhlack; D Bremen; H Przuntek; O Goetze; D Woitalla
Journal:  J Neural Transm (Vienna)       Date:  2006-04-11       Impact factor: 3.575

3.  Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone.

Authors:  T Keränen; A Gordin; M Karlsson; K Korpela; P J Pentikäinen; H Rita; E Schultz; L Seppälä; T Wikberg
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

4.  Inhibition of human erythrocyte and gastroduodenal catechol-O-methyltransferase activity by nitecapone.

Authors:  E Schultz; S Tarpila; A C Bäckström; A Gordin; E Nissinen; P Pohto
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

5.  Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa.

Authors:  J Dingemanse; K Jorga; G Zürcher; M Schmitt; G Sedek; M Da Prada; P Van Brummelen
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

6.  Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.

Authors:  M Merello; A J Lees; R Webster; M Bovingdon; A Gordin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-02       Impact factor: 10.154

7.  Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.

Authors:  Helena Heikkinen; Anu Varhe; Tarmo Laine; Jaakko Puttonen; Marjo Kela; Seppo Kaakkola; Kari Reinikainen
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

8.  Low catechol-O-methyltransferase activity in a Saami population.

Authors:  B Klemetsdal; B Straume; T Giverhaug; J Aarbakke
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

9.  The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise.

Authors:  S Sundberg; M Scheinin; A Illi; J Akkila; A Gordin; T Keränen
Journal:  Br J Clin Pharmacol       Date:  1993-11       Impact factor: 4.335

10.  Oleacein Intestinal Permeation and Metabolism in Rats Using an In Situ Perfusion Technique.

Authors:  Anallely López-Yerena; Maria Pérez; Anna Vallverdú-Queralt; Eleftherios Miliarakis; Rosa M Lamuela-Raventós; Elvira Escribano-Ferrer
Journal:  Pharmaceutics       Date:  2021-05-14       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.